enGene Holdings Inc. (NASDAQ:ENGNW) Stock Short Interest Falls 63.6%

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 1,699 shares, a drop of 63.6% from the August 31st total of 4,663 shares. Based on an average daily volume of 7,009 shares, the days-to-cover ratio is presently 0.2 days.

enGene Price Performance

Shares of ENGNW traded up $0.02 during trading hours on Monday, reaching $0.24. 9,715 shares of the company’s stock traded hands, compared to its average volume of 15,893. The business’s fifty day simple moving average is $0.28 and its two-hundred day simple moving average is $0.84. enGene has a twelve month low of $0.11 and a twelve month high of $4.20.

enGene Company Profile

enGene Inc is a clinical-stage biotechnology company developing non-viral gene therapies designed to treat diseases affecting mucosal tissues. The company’s proprietary DUAL (Decentralized Unit for Activated Loading) platform is intended to enable the local delivery of therapeutic DNA directly to target tissues, with the goal of producing treatment effects while limiting systemic exposure.

enGene’s lead investigational product is detalimogene voraplasmid, also known as EG-70, an intravesical gene therapy being developed for non-muscle-invasive bladder cancer.